The natriuretic peptide system: Kidney and cardiovascular effects

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 1, 2006, Pages 14-21

  Silver, Marc A ^a,b  

^a ADVOCATE CHRIST MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ANP; BNP; Heart failure; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GLYCERYL TRINITRATE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; URODILATIN;

CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CELL PROTECTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; FLUID BALANCE; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; HEART SURGERY; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; CHEMISTRY; HEART DISEASE; HOMEOSTASIS; KIDNEY DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

BIOLOGICAL MARKERS; HEART DISEASES; HEART FAILURE, CONGESTIVE; HOMEOSTASIS; HUMANS; KIDNEY DISEASES; NATRIURETIC PEPTIDES;

EID: 33645568427     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981; 28:89-94.
2. Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 1984; 118:131-139.
3. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81.
4. Sudoh T, Kangawa K, Minamino N, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168:863-870.
5. Cea LB. Natriuretic peptide family: new aspects. Curr Med Chem Cardiovasc Hematol Agents 2005; 3:87-98.
6. Munagala VK, Burnett JC, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004; 29:707-769. A comprehensive review that provides an overview of natriuretic peptide physiology and discusses BNP for the diagnosis, management and treatment of heart failure. Practical information for interpretation of BNP levels is provided and current controversies surrounding the use of nesiritide are discussed.
7. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 2004; 101:113-129. An excellent review discussing the structure and function of the natriuretic peptides as well as the important paracrine/autocrine functions of ANP and BNP with regard to the heart and coronary circulation.
8. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) 2005; 108:23-36. A comprehensive review discussing the current diagnostic, prognostic, HF management and treatment applications of cardiac NPs.
9. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328.
10. Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care 2004; 10:336-341. A review evaluating the clinical utility of cardiac NPs in diagnosis, prognosis, treatment guidance and therapy.
11. Scotland RS, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 2005; 105:85-93. An in-depth review of locally produced endothelial-derived CNP and its role in regulation of vascular tone, blood pressure and vascular regulation.
12. Kuhn M. Cardiac and intestinal natriuretic peptides: insights from genetically modified mice. Peptides 2005; 26:1078-1085. This review discusses the physiology of cardiac and intestinal natriuretic peptides and their guanylyl cyclase receptors, with special focus on autocrine/paracrine functions including anti-hypertrophic effects in the heart, and proliferation and differentiation in various tissues.
13. Houben AJ, Zander K, Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 2005; 19:411-419. An excellent review summarizing current understanding of BNP and the regulation and mechanism of action on the renal system.
14. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 24:341-356.
15. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10 (Suppl 3):1-30. Erratum in: Congest Heart Fail 2005; 11:102.
16. Boerrigter G, Burnett JC. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004; 13:643-652. A review discussing the hemodynamic, neurohormonal, renal and antifibrotic effects of BNP as well as the role of neutral endopeptidase inhibition in potential new treatment strategies for congestive HF.
17. Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 2001; 51:450-462.
18. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647-654. This randomized controlled trial of 452 patients presenting to the emergency department with dyspnea showed that a BNP level added to standard evaluation decreased the rate of hospital admission, length of stay and total cost of care.
19. Maisel A, Hollander JE, Guss D, et al. Primary Results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). J Am Coll Cardiol 2004; 44:1328-1333.
20. Hildebrandt P, Boesen M, Olsen M, et al. N-terminal pro brain natriuretic peptide in arterial hypertension: a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004; 6:313-317. In this study of 36 patients with arterial hypertension, NT-proBNP levels predicted increased left ventricular mass and risk of cardiovascular events.
21. Pedersen F, Raymond I, Kistorp C, et al. N-terminal pro-brain natriuretic peptide in arterial hypertension: a valuable prognostic marker of cardiovascular events. J Card Fail 2005; 11 (Suppl 5):70-75. This study provides results from a sample of subjects from the general population with hypertension and preserved left ventricular systolic function to suggest the utility of NT-BNP as a prognostic marker for cardiovascular morbidity and mortality.
22. Hutfless R, Kazanegra R, Madini M, et al. Utility of B-type natriuretic peptide in predicting post-operative outcomes in patients undergoing heart surgery. J Am Coll Cardiol 2004; 43:1873-1879. In this study of 98 patients undergoing open heart surgery, a BNP level of more than 385 pg/ml predicted both 1-year mortality and complications after operation, such as prolonged length of stay and need for intra-aortic balloon pump.
23. Silva JA, Chan AW, White CJ, et al. Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. Circulation 2005; 111:328-333. This small uncontrolled study suggests the need for further study to explore the potential for a BNP-guided strategy to aid in patient selection for renal artery revascularization.
24. Kubanek M, Malek I, Kautzner J, et al. The value of B-type natriuretic peptide and big endothel 1 for detection of severe pulmonary hypertension in heart transplant candidates. Eur J Heart Fail 2005. [Epub ahead of print] This study showed that serial BNP testing in heart transplant candidates may allow detection of pulmonary hypertension with reduced need for repeated right heart catheterizations.
25. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663. This analysis of 3346 middle-aged asymptomatic subjects in the Framingham Offspring Study showed that BNP levels were independently predictive of cardiovascular events and mortality.
26. Abassi Z, Karram T, Ellaham S, et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004; 102:223-241. A well referenced review of the physiological effects of NPs and their roles as biomarkers and as treatment, including vasopeptidase inhibitors such as omapatrilat.
27. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure: Nesiritide Study Group. N Engl J Med 2000; 343:246-253. Erratum in: N Engl J Med 2000; 343:1504. N Engl J Med 2000; 343:896.
28. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287:1531-1540. Erratum in: JAMA 2002; 288:577.
29. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003; 107:2697-2701.
30. Patel JB, Valencik ML, Pritchett AM, et al. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 2005; 289:H777-H784. This research using transgenic mice establishes the direct autocrine/paracrine cardioprotective function of natriuretic peptides on cardiomyocytes.
31. Kapoun AM, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94:453-461. This study demonstrated that BNP inhibits TGF-β induced fibrosis; these findings demonstrate that BNP has a direct inhibitory effect on cardiac fibroblasts and suggest that BNP functions as an anti-fibrotic factor to prevent cardiac remodeling in pathological conditions.
32. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37:1820-1826.
33. Chen HH, Schirger JA, Wright RS, et al. Pilot study assessing dose and tolerability of BNP (nesiritide) infusion post anterior myocardial infarction to prevent adverse left ventricular remodeling and heart failure. J Card Fail 2004; 10 (Suppl 4): Abstract 236.
34. Asakura M, Jiyoong K, Minamino T, et al. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of necrotic damage by ANP (J-WIND-ANP). Circ J 2004; 68:95-100.
35. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52:375-414.
36. Takagi G, Kiuchi K, Endo T, et al. Alpha-human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/ reperfusion in dogs. J Cardiovasc Pharmacol 2001; 36:22-30.
37. D'Souza SP, Yellon DM, Martin C, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003; 284:H1592-H1600.
38. Wakui S. Experimental study on myocardial protection by adjunct use of carperitide (hANP) in cardiac surgery. Ann Thorac Cardiovasc Surg 2005; 11:12-20.
39. Chen HH, Cataliotti A, Schirger JA, et al. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol 2005; 288:R093-R097. A study in anesthetized dogs with experimental overt congestive HF to compare the cardiovascular hemodynamics and renal effects of ANP, BNP and urodilatin infusions. This study determines the superiority of BNP over ANP and urodilatin to enhance renal function.
40. Koda M, Sakamoto A, Ogawa R. Effects of atrial natriuretic peptide at a low dose on water and electrolyte metabolism during general anesthesia. J Clin Anesth 2005; 17:3-7. In a randomized placebo-controlled double-blind study of 20 patients undergoing upper abdominal surgery, patients who received ANP had increased urinary electrolyte excretion and urine output compared with the control group.
41. Swärd K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004; 32:1310-1315. In this study of 61 patients who developed HF requiring pressors and subsequent renal failure after cardiac surgery, ANP infusion was associated with a decreased need for dialysis.
42. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110:1620-1625. A crossover study in 15 patients that showed that when added to furosemide, nesiritide had a neutral effect on urinary sodium excretion, urine output and GFR.
43. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004; 109:1680-1685. Canine model of experimental congestive HF comparing two doses of BNP plus furosemide with furosemide alone on neurohumoral and renal parameters.
44. Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose. J Card Fail 2005; 11: Abstract 427 (in press).
45. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111:1487-1491. Meta-analysis of five randomized controlled trials comparing the risk of increasing serum creatinine in patients treated with nesiritide with control.
46. Heywood JT. Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin. J Card Fail 2005; 11: Abstract 255 (in press).
47. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004; 94:595-601. Results from this multi-center randomized open-label pilot trial in 210 patients with advanced HF suggest that nesiritide is well tolerated in an outpatient setting and may be useful for prevention of recurrent decompensation and hospitalization.
48. Lenz TL, Foral PA, Malesker MA, et al. Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure. Pharmacotherapy 2004; 24:1137-1146. In this retrospective case-controlled study (n = 216) nesiritide was associated with significant reductions in healthcare resource utilization and complications, as evidenced by decreased intensive care unit length of stay and decreased rates of atrial fibrillation and renal dysfunction.
49. Chang R, Elatre W, Heywood J. Effect of nesiritide on length of hospital stay in decompensated heart failure. J Cardiovasc Pharmacol Ther 2004; 9: 173-177.
50. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293:1900-1905. This meta-analysis determined that nesiritide was associated with a non-statistically significant increased risk of 30-day mortality compared with non-inotrope therapy in three nesiritide trials that were not designed to assess mortality.
51. Elkayam U. Nesiritide may diminish the increased acute mortality risk associated with worsening renal function. Circulation 2005: Abstract 16338 (in press).
52. Abraham WT. Nesiritide and mortality risk: individual and pooled analyses of randomized controlled clinical trials. Rev Cardiovasc Med 2005; 6.
53. Abraham WT. Nesiritide does not increase 30-day or 6-month mortality risk. J Card Fail 2005; 11(6): Abstract 413 (in press).
54. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002; 39:798-803.
55. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149:209-216. As an observational database including 275 hospitals in the United States, ADHERE provides a unique opportunity to characterize patients, treatment patterns and outcomes in acute decompensated HF in a 'real-world' setting that is more representative of clinical practice than randomized controlled trials.
56. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46:57-64. This retrospective analysis of the largest database available to characterize hospitalized decompensated HF patients provides insight into the effect of vasoactive therapies on in-hospital mortality.
57. Chen HH, Redfield MM, Nordstrom LJ. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 2004; 10:115-119.
58. Cataliotti A, Schirger JA, Martin FL, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′5′-monophosphate and decreases mean arterial pressure. Circulation 2005; 112:836-840. This randomized crossover study in dogs demonstrated oral bioavailability of a novel conjugated form of BNP.